Bioresorbable drug-eluting magnesium-alloy scaffold for treatment of coronary artery disease
International Journal of Molecular Sciences , Volume 14 - Issue 12 p. 24492- 24500
The introduction of metallic drug-eluting stents has reduced the risk of restenosis and widened the indications of percutaneous coronary intervention in treatment of coronary artery disease. However, this medical device can induce hypersensitive reaction that interferes with the endothelialization and healing process resulting in late persistent or acquired malapposition of the permanent metallic implant. Delayed endotheliaization and malapposition may lead to late and very late stent thrombosis. Bioresorbable scaffolds (BRS) have been introduced to potentially overcome these limitations, as they provide temporary scaffolding and then disappear, liberating the treated vessel from its cage. Magnesium is an essential mineral needed for a variety of physiological functions in the human body and its bioresorbable alloy has the strength-to-weight ratio comparable with that of strong aluminum alloys and alloy steels. The aim of this review is to present the new developments in Magnesium BRS technology, to describe its clinical application and to discuss the future prospects of this innovative therapy.
|, , , , ,
|International Journal of Molecular Sciences
|Department of Cardiology
Campos, C., Muramatsu, T., Iqbal, A., Zhang, Y.-J., Onuma, Y., Garcia-Garcia, H., … Serruys, P. (2013). Bioresorbable drug-eluting magnesium-alloy scaffold for treatment of coronary artery disease. International Journal of Molecular Sciences (Vol. 14, pp. 24492–24500). doi:10.3390/ijms141224492